<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    15708180
   </pmid>
   <datecreated>
    <year>
     2005
    </year>
    <month>
     02
    </month>
    <day>
     14
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2005
    </year>
    <month>
     06
    </month>
    <day>
     16
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0167-5273
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       98
      </volume>
      <issue>
       3
      </issue>
      <pubdate>
       <year>
        2005
       </year>
       <month>
        Feb
       </month>
       <day>
        28
       </day>
      </pubdate>
     </journalissue>
     <title>
      International journal of cardiology
     </title>
     <isoabbreviation>
      Int. J. Cardiol.
     </isoabbreviation>
    </journal>
    <articletitle>
     Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation.
    </articletitle>
    <pagination>
     <medlinepgn>
      459-64
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      In addition to lowering lipid profile, statins have pleiotropic effects on improving vascular function. Changes of these pleiotropic effects and their relationship to lipid profile after withdrawal of statin treatment remained unclear.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      We investigated the changes of lipid profile and plasma concentrations of human soluble vascular cell adhesion molecule-1 (sVCAM-1) and human tissue type plasminogen activator (tPA) after withdrawal of statin treatment. Twenty-two patients (14 F, 8 M, aged 63+/-13 years) with hypercholesterolemia were treated with atorvastatin (ATOR; 10 mg/day) for 12 weeks. Blood samplings for serum lipid and markers were collected before, after and withdrawal of statin treatment.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      The total cholesterol, LDL-cholesterol and sVCAM-1 (from 394.4+/-251.7 to 321.0+/-198.9 ng/ml, p&lt;0.05) all decreased significantly and the tPA (from 9.47+/-3.57 to 11.62+/-3.99 ng/ml, p&lt;0.05) increased significantly after atorvastatin treatment. During the following 3 days after withdrawal of atorvastatin, the total cholesterol and LDL-cholesterol did not show any significant change. However, the plasma sVCAM-1 significantly elevated on day 2 (from 321.0+/-198.9 to 371.2+/-220.4 ng/ml, p&lt;0.05) and the plasma tPA significantly decreased on day 1 (from 11.62+/-3.99 to 10.52+/-3.55 ng/ml, p&lt;0.05) and day 3 (from 11.62+/-3.99 to 10.27+/-3.69 ng/ml, p&lt;0.05). Both the significant elevation of sVCAM-1 and decrease of tPA after withdrawal of atorvastatin treatment occurred within 3 days, while the serum cholesterol and LDL-chol levels did not have any significant change and were still within the therapeutic range.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      After 12 weeks of atorvastatin treatment, the beneficial pleiotropic effects can be demonstrated simultaneously with lowering the lipid profile. However, after withdrawal of atorvastatin, the beneficial pleiotropic effects are abrogated rapidly within days and are independent on elevation of serum cholesterol.
     </abstracttext>
    </abstract>
    <affiliation>
     Section of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Shih-Chuang 1st Rd., Kaohsiung 80708, Taiwan. wtlai@cc.kmu.edu.tw
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Lai
      </lastname>
      <forename>
       Wen-Ter
      </forename>
      <initials>
       WT
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lee
      </lastname>
      <forename>
       Kun-Tai
      </forename>
      <initials>
       KT
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Chu
      </lastname>
      <forename>
       Chih-Sheng
      </forename>
      <initials>
       CS
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Voon
      </lastname>
      <forename>
       Wen-Choi
      </forename>
      <initials>
       WC
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Yen
      </lastname>
      <forename>
       Hsueh-Wei
      </forename>
      <initials>
       HW
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Tsai
      </lastname>
      <forename>
       Li-Yu
      </forename>
      <initials>
       LY
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Sheu
      </lastname>
      <forename>
       Sheng-Hsiung
      </forename>
      <initials>
       SH
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     Ireland
    </country>
    <medlineta>
     Int J Cardiol
    </medlineta>
    <nlmuniqueid>
     8200291
    </nlmuniqueid>
    <issnlinking>
     0167-5273
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Cholesterol, LDL
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Heptanoic Acids
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Hydroxymethylglutaryl-CoA Reductase Inhibitors
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Pyrroles
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Vascular Cell Adhesion Molecule-1
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      110862-48-1
     </registrynumber>
     <nameofsubstance>
      atorvastatin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      57-88-5
     </registrynumber>
     <nameofsubstance>
      Cholesterol
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      EC 3.4.21.68
     </registrynumber>
     <nameofsubstance>
      Tissue Plasminogen Activator
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cholesterol
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cholesterol, LDL
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Fibrinolysis
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Heptanoic Acids
     </descriptorname>
     <qualifiername majortopicyn="Y">
      pharmacology
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hydroxymethylglutaryl-CoA Reductase Inhibitors
     </descriptorname>
     <qualifiername majortopicyn="Y">
      pharmacology
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypercholesterolemia
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pyrroles
     </descriptorname>
     <qualifiername majortopicyn="Y">
      pharmacology
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Tissue Plasminogen Activator
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Vascular Cell Adhesion Molecule-1
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="received">
     <year>
      2003
     </year>
     <month>
      Aug
     </month>
     <day>
      2
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="accepted">
     <year>
      2003
     </year>
     <month>
      Nov
     </month>
     <day>
      17
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2005
     </year>
     <month>
      2
     </month>
     <day>
      15
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2005
     </year>
     <month>
      6
     </month>
     <day>
      17
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2005
     </year>
     <month>
      2
     </month>
     <day>
      15
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pii">
     S0167527304001305
    </articleid>
    <articleid idtype="doi">
     10.1016/j.ijcard.2003.11.023
    </articleid>
    <articleid idtype="pubmed">
     15708180
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

